Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Items 901–1,000 of 1,000
Elemental mercury poisoning probably causes cortical myoclonus
Ragothaman, M., Kulkarni, G. B., Ashraf, V. V., Pal, P. K., Chickabasavaiah, Y. T., Shankar, S. K., Govindappa, S. S., Satishchandra, P., & Muthane, U. B. (2007) · Movement Disorders · doi:10.1002/mds.21641 · Cited by 9
Update on huntington’s disease
Berman, S., & Greenamyre, J. T. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-006-0019-6 · Cited by 11
Barwell, T., Raina, S., Page, A., MacCharles, H., & Seroude, L. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad098 · Cited by 8
Why mammalian wound‐healing researchers may wish to turn to D rosophila as a model
Muñoz, V. F. L., López‐Domènech, S., & Paricio, N. (2014) · Experimental Dermatology · doi:10.1111/exd.12472 · Cited by 8
Anglada‐Huguet, M., Giralt, A., Rué, L., Alberch, J., & Xifró, X. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.04.002 · Cited by 11
Epigenetics and cognitive disorders—translational aspects
Coppedè, F. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800226-1.00004-6 · Cited by 8
Treatment and management issues in ataxic diseases
Perlman, S. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-51892-7.00046-2 · Cited by 9
Cell cycle regulation by the pro-apoptotic gene Scotin
Gupta, R. K., Tripathi, R., Bhupana, J. N., Srinivas, U. K., & Shashidhara, L. S. (2008) · Cell Cycle · doi:10.4161/cc.6407 · Cited by 8
Michno, K., van de Hoef, D. L., Wu, H., & Boulianne, G. L. (2005) · Clinical Genetics · doi:10.1111/j.1399-0004.2005.00448.x · Cited by 10
“In fact, not only did inhibition of deacetylases suppress the Drosophila HD phenotype (57, 61), subsequent studies have shown that it is also effective in mammals (62).”
BackgroundLiévens, J.-C., & Birman, S. (2003) · médecine/sciences · doi:10.1051/medsci/2003195593 · Cited by 8
“Ces modèles consistent à exprimer un fragment amino-terminal du gène huntingtine humain contenant une répétition élevée du codon CAG, sous le contrôle d’un promoteur neuronal ou spécifique de la rétine [9, 11].”
BackgroundInfluentialNiewiadomska-Cimicka, A., Hache, A., Gras, S. L., Keime, C., Ye, T., Eisenmann, A., Harichane, I., Roux, M. J., Messaddeq, N., Clérin, E., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00892-1 · Cited by 7
“Mutant huntingtin in HD has also been shown to alter various HAT activities, either by direct interaction (e.g. CBP, P300 and PCAF [99]) or through sequestration into polyQ aggregates (e.g. CBP [100]).”
Kim, S. A., D’Acunto, V. F., Kokona, B., Hofmann, J. L., Cunningham, N. R., Bistline, E. M., Garcia, F. J., Akhtar, N., Hoffman, S. H., Doshi, S. H., et al. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00518 · Cited by 7
Modelling in miniature: Using Drosophila melanogaster to study human neurodegeneration
Lambrechts, R. A., Faber, A. I. E., & Sibon, O. C. M. (2017) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2018.09.004 · Cited by 10
Haga‐Yamanaka, S., Nuñez‐Flores, R., Scott, C. A., Perry, S., Chen, S. T., Pontrello, C. G., Nair, M. G., & Ray, A. (2023) · eLife · doi:10.7554/elife.86823 · Cited by 8
“Previous studies indicate that the inhibition of HDACs counters the acetyltransferase inhibitory activity of the polyglutamine-domain of the Htt protein, which binds to p300, P/CAF, and CBP ( Steffan et al., 2001 ).”
BackgroundMethodInfluentialYon, M., Decoville, M., Sarou‐Kanian, V., Fayon, F., & Birman, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-66218-z · Cited by 7
Turkman, N., Xu, S., Huang, C.-H., Eyermann, C. E., Salino, J., & Khan, P. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02064 · Cited by 8
Autosomal Dominant Spinocerebellar Ataxias and Episodic Ataxias
Taroni, F., Chiapparini, L., & Mariotti, C. (2012) · Springer eBooks · doi:10.1007/978-94-007-1333-8_101 · Cited by 7
Lipids and Lipid Signaling in Drosophila Models of Neurodegenerative Diseases
Cho, K. S., Bang, S. M., & Toh, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410527-0.00026-0 · Cited by 14
Huntington’s disease: Towards disease modification – Gaps and bridges, facts and opinions
Reilmann, R. (2012) · Basal Ganglia · doi:10.1016/j.baga.2012.09.004 · Cited by 7
“in beneficial effects in vitro and in vivo in tgHD preclinical models [77].”
BackgroundC. elegans comme modèle pour les maladies dégénératives héréditaires humaines
Néri, C., & Ségalat, L. (2003) · médecine/sciences · doi:10.1051/medsci/200319121218 · Cited by 14
“Des modèles cellulaires [26, 38] et des modèles murins [39, 40] ou de drosophile [41] ont déjà permis d’identifier un certain nombre de composés à potentiel thérapeutique comme les inhibiteurs des histone désacétylases (effet sur la transcription), la minocycline (effet sur les caspases), et la créatine ou l’IGF1 (ins…”
BackgroundNovel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Tremolizzo, L., Rodriguez‐Menendez, V., Conti, E., Zoia, C., Cavaletti, G., & Ferrarese, C. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990535 · Cited by 8
“Finally, abnormal huntingtin was able to decrease H3 and H4 acetylation in PC12 cells reversed by butyrate treatment [99].”
BackgroundInfluentialSpinocerebellar Ataxia Type 7: Clinical Features to Cellular Pathogenesis
Garden, G. A., Truant, R., Ellerby, L., & Spada, A. R. L. (2006) · Elsevier eBooks · doi:10.1016/b978-012369462-1/50028-4 · Cited by 8
Kosol, S., Contreras-Martos, S., Piai, A., Váradi, M., Lázár, T., Békési, A., Lebrun, P., Felli, I. C., Pierattelli, R., & Tompa, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-62069-w · Cited by 7
Lin, Y.-H., Maaroufi, H. O., Kučerová, L., Rouhová, L., Filip, T., & Žurovec, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651367 · Cited by 7
Ansaloni, A., Wang, Z., Jeong, J. S., Ruggeri, F. S., Dietler, G., & Lashuel, H. A. (2014) · Angewandte Chemie · doi:10.1002/ange.201307510 · Cited by 7
Pulst, S.-M. (2003) · Elsevier eBooks · doi:10.1016/b978-012566652-7/50004-6 · Cited by 12
From target identification to drug screening assays for neurodegenerative diseases
Zuccato, C., Tartari, M., Goffredo, D., Cattaneo, E. F., & Rigamonti, D. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.03.010 · Cited by 9
Cunha‐Oliveira, T., Lusa, I., & Cristina, A. (2012) · InTech eBooks · doi:10.5772/32728 · Cited by 7
“…transcriptional processes, through direct interaction with CREB-binding protein (CBP) (Steffan et al. 2000) and with TATA box-binding protein (TBP)-associated factor TAF4/TAFII130 (Dunah et al. 2002;Shimohata et al. 2000), leading to an increase in mHtt-induced cytotoxicity (Steffan et al. 2001).”
BackgroundButyrate: A Review on Beneficial Pharmacological and Therapeutic Effect
Singh, D. P., & Gupta, S. (2020) · Current Nutrition & Food Science · doi:10.2174/1573401316999201029210912 · Cited by 6
Advantages and differences among various animal models of Huntington’s disease
Zhu, Y., Yang, W., & Yan, S. (2024) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2024.13 · Cited by 7
Self-citationModulation of Huntington’s Disease in Drosophila
Subhan, I., & Siddique, Y. H. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210412155508 · Cited by 6
Saha, S., Dey, M. J., Promon, S. K., & Araf, Y. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.09.001 · Cited by 9
“As a result, it impacts histone deacetylase (HDAC) inhibitors, an inhibitor that prevents neurodegeneration in cells [26,27].”
BackgroundHunting for the function of Huntingtin
Zheng, Q., & Joinnides, M. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.003376 · Cited by 7
“Previous mouse models that are null for the murine Htt homolog, Hdh, have been difficult to study since they die very early in embryogenesis (Duyao et al., 1995; Nasir et al., 1995; Zeitlin et al., 1995).”
BackgroundTak, Y. K., Naoghare, P. K., Han, E., & Song, J. M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22540 · Cited by 6
Euler, P., Friedrich, B., Ziegler, R., Kuhn, A., Lindenberg, K. S., Weiller, C., & Zucker, B. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.080 · Cited by 8
Polyalanine and Polyglutamine Diseases: Possible Common Mechanisms?
Abu‐Baker, A., & Rouleau, G. A. (2006) · Elsevier eBooks · doi:10.1016/b978-012369462-1/50034-x · Cited by 6
Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice
Morozko, E. L., Ochaba, J., Hernandez, S. J., Lau, A., Sanchez, I., Orellana, I., Kopan, L., Crapser, J. D., Duong, J. H., Overman, J., et al. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-180329 · Cited by 7
“Many HD-associated studies have focused on mHTT exon 1 protein (mHTTex1p) due to its robust effects on mHTT accumulation and aggregation, and on behavioral and biochemical deficits associated with HD in mice and flies [10, 11].”
Self-citationTranscriptional Dysregulation in Huntington’s Disease
Duce, J. A., Hartog, C., Elliston, L. A., Neal, J., Nicholson, L. F. B., & Jones, A. L. (2002) · Advances in behavioral biology · doi:10.1007/978-1-4615-0715-4_49 · Cited by 6
Solving the Puzzle of Neurodegeneration
Wolfe, M. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00001-8 · Cited by 8
Machado-Joseph Disease / Spinocerebellar Ataxia Type 3
Nbrega, C., & de Almei, L. P. (2012) · InTech eBooks · doi:10.5772/28576 · Cited by 18
“…al., 2008) suggesting that transcriptional dysregulation may be a central feature of the neurodegenerative mechanism in the polyglutamine disorders (Steffan et al., 2001; Nucifora et al., 2001; Minamiyama et al., 2004; La Spada et al., 2001; Hughes et al., 2001; Yamada et al., 2000; Lim et al.,…”
Alleviating neurodegeneration in Drosophila models of PolyQ diseases
Long, Z., Tang, B., & Jiang, H. F. (2014) · Cerebellum & Ataxias · doi:10.1186/2053-8871-1-9 · Cited by 8
“These findings present therapeutics for polyQ diseases, even after the onset of symptoms, treatment with HDAC inhibitors are still capable of slowing or arresting the progressive neurodegeneration [70].”
BackgroundSingh, A. K., & Kundu, T. K. (2026) · ACS Omega · doi:10.1021/acsomega.5c00905 · Cited by 6
Modeling human neurodegenerative disorders in Drosophila: strategies and translational opportunities
Mohamed, S. A., & Badr, O. A. M. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11844-5 · Cited by 5
Animal models of amyotrophic lateral sclerosis and Huntington’s disease
Islam, A. M. T., Kwak, J., Jung, Y. J., & Kee, Y. (2014) · Genes & Genomics · doi:10.1007/s13258-014-0188-7 · Cited by 5
“Httex1pQ93 Tg Human HTT-N (65aa) with 93 polyQ, under elav promoter, using Gal4/UAS system Photoreceptor degeneration, reduced lifespan Steffan et al. (2001)”
MethodThe Promise of Epigenetic Editing for Treating Brain Disorders
González-Molina, L. A., Dolga, A. M., Rots, M. G., & Sarno, F. (2025) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-75980-2_4 · Cited by 6
The Role of MicroRNAs in Neurodegeneration: Insights from Huntington’s Disease
Mansour, R. M., Shaker, A. A. S., Abulsoud, A. I., Mageed, S. S. A., Ashraf, A., Elsakka, E. G. E., Dahab, M. I., Sadek, M. M., Awad, F. A., Lutfy, R. H., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04750-7 · Cited by 7
“This dysregulation of CREB signaling results in altered expression of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), contributing to neuronal dysfunction and degeneration [29, 30] (Fig.”
Huntingtin with an expanded polyglutamine repeat affects the Jab1-p27(Kip1) pathway
Cong, S., Pepers, B. A., Zhou, T., Kerkdijk, H., Roos, R. A. C., van Ommen, G. B., & Dorsman, J. C. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.008 · Cited by 6
The current state of amyloidosis therapeutics and the potential role of fluorine in their treatment
Dabur, M., Loureiro, J. A., & Pereira, M. D. C. (2022) · Biochimie · doi:10.1016/j.biochi.2022.08.003 · Cited by 6
The anti-leprosy drug clofazimine reduces polyQ toxicity through activation of PPARγ
Li, X., Hernández, I. H., Koyuncu, S., Kis, B., Häggblad, M., Lidemalm, L., Abbas, A. A., Sramkó, B., Göblös, A., Brautigam, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105124 · Cited by 7
Rosenstock, T. R. (2014) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.886877 · Cited by 6
Milano, W., Tecce, M. F., & Capasso, A. (2017) · Diseases and Disorders · doi:10.15761/jdd.1000104 · Cited by 4
“Recently, it has been shown that inhibition of histone deacetylase enzymes (HDACs) induces neuroprotective effects in neurodegenerative disorders [14,15].”
BackgroundNonmammalian Models of Huntington’s Disease
Chongtham, A., Barbaro, B. A., Filip, T., Syed, A., Huang, W., Smith, M. R., & Marsh, J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_5 · Cited by 6
Self-citationXiao, C., Qiu, S., Robertson, R. M., & Seroude, L. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.12.009 · Cited by 5
Dhankhar, J., Agrawal, N., & Shrivastava, A. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577801 · Cited by 5
Non-mammalian animal models of Parkinson's disease for drug discovery
Lim, K. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903527675 · Cited by 5
“However, it is noteworthy to highlight the finding that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor that can ameliorate motor deficits in a mouse model of Huntington’s disease (HD), was originally uncovered in a Drosophila model of HD [70].”
BackgroundHuntington’s Disease: From the Physiological Function of Huntingtin to the Disease
Borgs, L., Juliette, D. L., Malgrange, B., & Nguye, L. (2012) · InTech eBooks · doi:10.5772/31789 · Cited by 5
RetractedKatsuno, M., & Sobue, G. (2004) · Neuron · doi:10.1016/s0896-6273(04)00110-2 · Cited by 5
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50018-8 · Cited by 5
Hereditary spinocerebellar ataxias: number, prevalence, and treatment prospects.
Soong, B. (2004) · PubMed · Cited by 5
Paldino, E., Montalesi, E., Fiocchetti, M., Dioguardi, F., Venditti, I., Olivieri, E., Marino, M., & Fusco, F. R. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115639 · Cited by 5
Donoghue, S. E., Wright, J. L., Voss, A. K., Lockhart, P. J., & Amor, D. J. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108360 · Cited by 5
Intersecting impact of CAG repeat and huntingtin knockout in stem cell-derived cortical neurons
Stocksdale, J. T., Leventhal, M. J., Lam, S., Xu, Y., Wang, Y., Wang, K. Q., Thomas, R., Faghihmonzavi, Z., Raghav, Y., Smith-Geater, C., et al. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106914 · Cited by 8
“In this cluster, the HTT protein is a node connected to its known interactor CREBBP/CBP (Steffan et al., 2001) as well as its downstream target, FOS.”
Self-citationLife Extension in Drosophila by Histone Deacetylase Inhibitors
Vaiserman, A. M., & PASYUKOVA, E. G. (2015) · Healthy ageing and longevity · doi:10.1007/978-3-319-18326-8_11 · Cited by 4
Parlato, R., Mandl, C., Hölzl‐Wenig, G., Liss, B., Tucker, K. L., & Ciccolini, F. (2014) · Neurogenesis · doi:10.4161/23262125.2014.970883 · Cited by 6
Therapeutic Strategies in Huntington's Disease
Kanazawa, I. (2006) · Journal of Clinical Neurology · doi:10.3988/jcn.2006.2.4.213 · Cited by 6
“Although the transcription processes in cells are balanced between histone acetylation and deacetylation, this reaction may be shifted to deacetylation catalyzed by histone deacetylase (HDAC) in HD model and probably in polyglutamine diseases.(64) Correction of this shift could be, therefore, a suitable strategy for a…”
BackgroundRai, S., & Tapadia, M. G. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.857257 · Cited by 6
Epigenetic treatment of neurodegenerative disorders
Martínez-Iglesias, O. A., & Cacabelos, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816422-8.00013-1 · Cited by 4
Shelbourne, P., & Monckton, D. G. (2006) · Elsevier eBooks · doi:10.1016/b978-012369462-1/50036-3 · Cited by 5
Therapeutic strategies in Huntington?s disease
Alberch, J., Canals, J. M., & Pérez‐Navarro, E. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.4.449 · Cited by 4
“Interestingly, the effects of the mutant Huntingtin can be redressed by histone deacetylase inhibitors in the fly and mouse model of HD [38,39].”
BackgroundLinking model systems to cancer therapeutics: the case of Mastermind
Yedvobnick, B., & Moberg, K. H. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.005520 · Cited by 4
“(Steffan et al., 2001) used such a model to show that smallmolecule inhibitors of the histone deacetylase class of enzymes (HDACs) protect against Htt-induced neurodegeneration.”
Neuroprotection by dietary restriction and the PPAR transcription complex
Mobbs, C. V., Moreno, C. L., Kim, E., Ekasumara, N., & Marcellino, B. K. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0035-8 · Cited by 4
Chan, H. Y. E. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02292-x · Cited by 4
Histone deacetylase inhibitors: pharmacotherapeutic implications as epigenetic modifier
Vishwakarma, P., Kumar, A., Sharma, M., Garg, M., & Saxena, K. (2014) · International Journal of Basic & Clinical Pharmacology · doi:10.5455/2319-2003.ijbcp20140236 · Cited by 3
Gene Therapy-Based Modeling of Neurodegenerative Disorders: Huntington’s Disease
Young, D. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3271-9_27 · Cited by 4
HSF1 Activation by Small Chemical Compounds for the Treatment of Neurodegenerative Diseases
Fujikake, N., Takeuchi, T., & Nagai, Y. (2016) · Springer eBooks · doi:10.1007/978-4-431-55852-1_14 · Cited by 4
“Treatment with HDAC inhibitors, such as trichostatin A and sodium phenylbutyrate, has indeed been shown to exert therapeutic effects against various models of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s diseases, ALS, and the polyQ diseases (Ricobaraza et al. 2009; Kontopoulos et al. 2006; R…”
BackgroundPerlman, S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.10.1637 · Cited by 5
“Candidate agents (suberoylanilide hydroxamic acid [SAHA], phenylbutyrate, valproic acid) are being looked at in animal models of HD [56,57] but not yet in the SCAs.”
BackgroundATRX : From Chromatin Remodeling to Disease
Magaña‐Acosta, M., & Valadéz-Graham, V. (2025) · genesis · doi:10.1002/dvg.70031 · Cited by 5
Epigenetic mechanisms in Huntington's disease
Thomas, E. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813796-3.00004-3 · Cited by 3
Bhatnagar, A., Karnay, A. M., & Elefant, F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91909-8.00015-3 · Cited by 3
Chongtham, A., & Agrawal, N. (2024) · Dose-Response · doi:10.1177/15593258241291652 · Cited by 3
“24,25 These fl ies were crossed to the pan-neuronal elav driver w; P {w +mW.hs = GawB}elavC155.”
BackgroundInfluentialThe advances in acetylation modification in senescence and aging-related diseases
Xu, M., Wang, W., Lu, S., Xiong, M., Zhao, T., Yu, Y., Song, C., Yang, J., Zhang, N., Cao, L., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1553646 · Cited by 6
Penney, E. B., & McCabe, B. D. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00024-5 · Cited by 3
Histone deacetylase (Rpd3) regulates Drosophila early brain development via regulation of Tailless
Das, P., & Bhadra, M. P. (2020) · Open Biology · doi:10.1098/rsob.200029 · Cited by 5
“There are pieces of evidence of memory amelioration in mouse models [22] and polyglutamine-dependent neurodegeneration correction in Drosophila [23] upon HDAC inhibitor treatments.”
Roy, S. K., & Liu, X. (2021) · Neuroscience & Medicine · doi:10.4236/nm.2021.121003 · Cited by 4
“Interestingly, there are some HDAC inhibitors such as suberoylanilidehydroxamic acid, sodium butyrate, and phenyl-butyrateare supposed to increase gene expression, have shown well efficacy in various neurodegenerative diseases [55]-[60].”
Polyglutamine disease in peripheral tissues
Barwell, T., & Seroude, L. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad138 · Cited by 4
Delfino, L., Campesan, S., Fedele, G., Green, E. W., Giorgini, F., Kyriacou, C. P., & Rosato, E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2249-0_25 · Cited by 2
Basso, M. (2012) · InTech eBooks · doi:10.5772/31579 · Cited by 2
“On one side, mHTT recruits histone acetyl transferases (HATs), such as CBP, in intranuclear aggregates and reduces their ability to acetylate histones; on the other side, mHTT facilitates polycomb repressive complex 2 (PRC2), which methylates histone H3 in lysine 27 and mediates transcriptional repression (Seong et al…”
BackgroundInfluentialNon-coding RNAs in polyglutamine disorders: friend or foe?
Sengupta, S., & Ganesh, S. (2008) · Journal of Biosciences · doi:10.1007/s12038-008-0047-2 · Cited by 3
“33(2), June 2008 factor, SP1 transcription factor and p53, suggesting that such abnormal interactions could alter transcriptional regulation in the affected neurons (Cha 2000; Nucifora et al 2001; Steffan et al 2001).”
BackgroundHuntington’s Disease: Molecular Pathogenesis and New Therapeutic Perspectives
Perandones, C., & Muñoz-Sanjuán, I. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6455-5_6 · Cited by 3
Kosinski, C. M., & Landwehrmeyer, G. B. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.058 · Cited by 3
A link between chromatin condensation mechanisms and Huntington's disease: connecting the dots
Lokhande, S., Patra, B. N., & Ray, A. (2016) · Molecular BioSystems · doi:10.1039/c6mb00598e · Cited by 5
Nandi, N., Zaidi, Z., Tracy, C., & Krämer, H. (2022) · eLife · doi:10.7554/elife.72169 · Cited by 3
“…required for binding to and activating Cdk5 ( Connell-Crowley et al., 2007 ), a kind gift from Edward Giniger, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, YFP MYC - Rab5 ( Dunst et al., 2015 ) and UAS- Htt- exon1-Q93 ( Steffan et al., 2001 ), abbreviated UAS-Htt.”
Bolger, T. A., Cohen, T., & Yao, T. (2007) · Springer eBooks · doi:10.1007/978-0-387-40049-5_6 · Cited by 4
Epigenetics – Chromatin Structure and Rett Syndrome
Levenson, J. M., & Wood, M. A. (2008) · Elsevier eBooks · doi:10.1016/b978-012370509-9.00043-7 · Cited by 3
Genetics of Aging in Drosophila
Partridge, L., & Pletcher, S. D. (2003) · Springer eBooks · doi:10.1007/978-94-017-0671-1_6 · Cited by 4
Novel trends in orphan market drug discovery amyotrophic lateral sclerosis as a case study
Clark, J. E., Brennan, A., Ramesh, T., & Heywood, J. A. (2002) · Frontiers in bioscience · doi:10.2741/a762 · Cited by 3
Prognosis in the acute motor axonal form of Guillain-Barre syndrome
Gabriel, C. M. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.055376 · Cited by 4
Therapeutic Prospects for Polyglutamine Disease
Pennuto, M., & Fischbeck, K. H. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch40 · Cited by 3
Pathogenesis of Polyglutamine Diseases
Sahashi, K., & Katsuno, M. (2018) · Wiley eBooks · doi:10.1002/9780470015902.a0021486.pub2 · Cited by 4
Manto, M., & Jissendi, P. (2009) · Elsevier eBooks · doi:10.1016/b978-008045046-9.01521-7 · Cited by 3
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.